Skip to main content

Table 1 Prevalence of symptoms’ persistence at three months in the whole study population and according to treatments subsequently prescribed

From: Role of nutrient supplements in children with post-COVID condition: a retrospective preliminary observation and narrative review

 

All

1250

MEP + LF

152

LF

18

MEP

9

P value

Mean Age (y)

6.8

7.1

6.9

7.1

> 0.05

Persisting Symptoms

     

Low grade fever

8 (0.6)

2 (1.3)

2 (11.1)

0

> 0.05

Anosmia

11 (0.9)

5 (3.3)

1 (5.6)

1 (11.1)

> 0.05

Dysgeusia

11 (0.9)

4 (2.6)

2 (11.1)

0

> 0.05

Chronic Cough

16 (1.3)

5 (3.3)

1 (5.6)

0

> 0.05

Dyspnea with mild efforts

77 (6.2)

38 (25)

9 (50)

3 (33.3)

> 0.05

Tachycardia

20 (1.6)

12 (7.9)

1 (5.6)

1 (11.1)

> 0.05

Joint Pains

31 (2.5)

14 (9.2)

5 (27.8)

1 (11.1)

> 0.05

Muscle Pains

53 (4.2)

28 (18.4)

8 (44.4)

0

> 0.05

Chronic Headache

69 (5.5)

43 (28.3)

8 (44.4)

2 (22.2)

> 0.05

Chronic gastrointestinal problems

56 (4.5)

30 (19.7)

4 (22.2)

1 (11.1)

> 0.05

Rashes

14 (1.1)

7 (4.6)

1 (5.6)

1 (11.1)

> 0.05

Easily fatigued with mild efforts

15 (1.2)

6 (3.9)

1 (5.6)

0

> 0.05

Concentrations and Memory difficulties

31 (2.5)

19 (12.5)

2 (11.1)

0

> 0.05

Unusual Fatigue

162 (13)

93 (61.2)

11 (61.1)

3 (33.3)

> 0.05

Chest pain

29 (2.3)

14 (9.2)

2 (11.1)

1 (11.1)

> 0.05

  1. MEP: Multi-Element Product
  2. LF: lactoferrin